Angiogenesis in Rheumatoid Arthritis: Pathogenic and Clinical Significance

Journal of Investigative Medicine

Volumn 46, Issue 2, 1998, Pages 27-41

  Szekanecz, Zoltan ^a,b   Szegedi, Gyula ^b   Koch, Alisa E ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; GROWTH PROMOTOR;

ANIMAL; BIOLOGICAL MODEL; EXTRACELLULAR MATRIX; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; EXTRACELLULAR MATRIX; GROWTH SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031992840     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (180)

1. Colville-Nash PR, Scott DL. Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992;51:919-25.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-7.
3. Polverini PJ. Macrophage-induced angiogenesis: a review. In: Sorg C, ed. Macrophage-derived cell regulatory factors. Cytokines. Basel: Karger, 1989;1:54-73.
4. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991;53:217-39.
5. Sunderkötter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenic factors. Pharmac Ther 1991;51:195-216.
6. Folkman J. Angiogenesis - retrospect and outlook. EXS 1991;59:4-13.
7. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;332:1277-87.
8. Szekanecz Z, Haines GK, Lin TR, Harlow LA, Goerdt S, Rayan G, Koch AE. Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 1994;37:221-31.
9. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan J, Leibovich SJ. Immunolocalization of leukocyte and endothelial adhesion molecules in human rheumatoid and osteoarthritic synovial tissue. Lab Invest 1991;64,313-20.
10. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmac Ther 1994;63:265-311.
11. Diaz-Flores L, Gutierrez R, Varela H. Angiogenesis: an update. Histol Histopathol 1994;9:807-43.
12. Schweigerer L. Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 1995;73:497-508.
13. Montesano R, Pepper MS, Vassalli J-D, Orci L. Modulation of angiogenesis in vitro. EXS 1991;59:129-36.
14. Jackson CJ, Jenkins K, Schrieber L. Possible mechanisms of type I collagen-induced vascular tube formation. EXS 1992;59:198-204.
15. Szekanecz Z, Shah MR, Harlow LA, Pearce WH, Koch AE. Interleukin-8 and tumor necrosis factor-alpha are involved in human aortic endothelial cell migration. Pathobiology 1994; 62:134-39.
16. Szekanecz Z, Shah MR, Pearce WH, Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4. Agents Actions 1994;42:159-62.
17. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-9.
18. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987;329:630-2.
19. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
20. Madri JA, Williams KS. Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 1983;97:153-65.
21. Hu DE, Hori Y, Fan T-PD. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993;17:135-43.
22. Sano H, Forough R, Maier JAM, Case JP, Jackson A, Engleka K. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990;110:1417-26.
23. Byrd V, Zhao XM, McKeehan WL, Miller GG, Thomas JW. Expression and functional expansion of fibroblast growth factor receptor T cells in rheumatoid synovium and peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:914-22.
24. Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE, Rosenbaum JT. Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995;73:339-46.
25. Goddard DH, Grossman SL, Williams WV, Weiner DB, Gross JL, Eidsvoog K. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 1992;35:1296-303.
26. Hosaka S, Shah MR, Barquin N, Haines GK, Koch AE. Expression of basic fibroblast growth factor and angiogenin in arthritis. Pathobiology 1995;63:249-56.
27. Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
28. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
29. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
30. Nagashima M, Yoshino S, Ishiwata T, Asano G. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 1995;22:1624-30.
31. Rosen EM, Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp Soc Exp Biol 1993;47P:227-34.
32. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, Polverini P, Rosen EM. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-41.
33. Koch AE, Halloran MM, Hosaka S, Shah MR, Haskell CJ, Baker SK, Panos RJ, Haines GK, Bennett GL, Pope RM, Ferrara N. Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 1996;39:1566-75.
34. Sato N, Beitz JG, Kato J, Yamamoto M, Clark JW, Calabresi P, Frackelton AR Jr. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993;142:1119-30.
35. Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Sem Arthritis Rheum 1991;21:191-9.
36. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986;83:7297-301.
37. Oikawa T, Onozawa C, Sakaguchi M, Monta I, Murota S. Three isoforms of platelet-derived growth factors all have the capability to induce angiogenesis in vivo. Biol Pharm Bull 1994;17:1686-8.
38. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K, Heldin CH. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992;7:261-6.
39. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994;90:649-52.
40. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. J Clin Invest 1989;83:1267-76.
41. Takeuchi M, Otsuka T, Matsui N, Asai K, Hirano T, Moriyama A. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994;37:662-72.
42. Kusada J, Otsuka T, Matsui N, Hirano T, Asai K, Kato T. Immuno-reactive human epidermal growth factor (h-EGF) in rheumatoid synovial fluids. Nippon Seikeigeka Gakkai Zasshi 1993;67:859-65.
43. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996;81:150-5.
44. Keyszer GM, Heer AH, Kriegsmann J, Geiler T, Keysser C, Gay RE, Gay S: Detection of insulin-like growth factor I and II in synovial tissue specimens of patients with rheumatoid arthritis and osteoarthritis by in situ hybridization. J Rheumatol 1995;22:275-81.
45. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988;157:793-800.
46. Wright JK, Cawston TE, Hazleman BL. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta 1991;1094:207-10.
47. Hamilton JA, Piccoli DS, Iizer T, Butler DM, Croatto M, Royston AK. Transforming growth factor beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostaglandin E2 production, in human synovial fibroblasts. Proc Natl Acad Sci USA 1991;88:7180-4.
48. Chu CQ, Field M, Abney E, Zheng RQH, Allard S, Feldmann M, Maini RN. Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991;86:380-6.
49. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ-W, Rayan G, Koch AE. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995;76:187-94.
50. Bucht A, Larsson P, Weisbrot L, Thorne C, Pisa P, Smedegard G, Keystone EC, Gronberg A. Expression of interferon-gamma (IFN-gamma), IL-10, IL-12 and transforming growth factor-beta (TGF-beta) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clin Exp Immunol 1996;103:357-67.
51. Wahl SM, Allen JB, Wong HL, Dougherty SF, Ellingsworth LR. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 1990;145:2514-9.
52. Fava RA, Olsen NJ, Postlethwaite AE, Broadley KN, Davidson JM, Nanney LB. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: Implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med 1991;173:1121-32.
53. Brandes ME, Allen JB, Ogawa Y, Wahl SM. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991;87:1108-13.
54. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997;233:231-7.
55. Halloran MM, Haskell CJ, Woods JM, Hosaka S, Koch AE. Interleukin-13 is an endothelial chemotaxin. Pathobiology, in press.
56. Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK, Pope RM, Strieter RM. The synovial tissue macrophage as a source of the chemotactic cytokine interleukin-8. J Immunol 1991;147:2187-95.
57. Koch AE, Polverini PJ, Leibovich SJ. Stimulation of neovascularization by human rheumatoid synovial tissue macrophages. Arthritis Rheum 1986;29:471-9.
58. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17:4015-23.
59. Saxne T, Palladino MA Jr., Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5.
60. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Annals Rheum Dis 1990;49:665-7.
61. Lupia E, Montrucchio G, Battaglia E, Modena V, Camussi G. Role of tumor necrosis factor-alpha and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. Eur J Immunol 1996;26:1690-4.
62. Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis. Regulation by cytokines and possible clinical importance. J Investig Med 1996;44:124-35. 1996.
63. Abbot SE, Kaul A, Stevens CR, Blake DR. Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression. Arthritis Rheum 1992;35:401-6.
64. Lindsley HB, Smith DD, Davis LS, Koch AE, Lipsky PE. Regulation of the expression of adhesion molecules by human synoviocytes. Semin Arthritis Rheum 1992;21:330-4.
65. Brennan FM, Field M, Chu CQ, Feldmann M, Maini RN. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991;30:76-80.
66. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
67. Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 1986;65:293-302.
68. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990;87:3092-6.
69. Rosen EM, Liu D, Setter E, Bhargava M, Goldberg ID. Interleukin-6 stimulates motility of vascular endothelium. EXS 1991;59:194-205.
70. Sachs L. Angiogenesis - cytokines as part of a network. EXS 1991;59:20-2.
71. Houssiau FA, Devogelaer J-P, Van Damme J, De Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
72. Guerne P-A, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989;83:585-92.
73. Field M, Chu C, Feldmann M, Maini RN. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991;11:45-50.
74. Isomaki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1693-1702.
75. Woods JM, Haines GK, Shah MR, Koch AE. Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996;39:S129.
76. McInnes IB, Al-Mughales J, Field M, Leung BP, Huang F, Dixon R, Sturrock RD, Wilkinson PC, Liew FY. The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med 1996;2:175-82.
77. Alvaro-Garcia JM, Zvaifler NJ, Firestein GS. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989;170:865-75.
78. Strieter RM, Kunkel SL, Shanafelt AB, Arenberg DA, Koch AE, Polverini PJ. The role of C-X-C chemokines in regulation of angiogenesis. In: Koch AE. Strieter RM, eds. Chemokines in disease. R.G. Landes Company: Austin, 1996;195-209.
79. Koch AE, Kunkel SL, Strieter RM. Chemokines in arthritis. In: Koch AE. Strieter RM, eds. Chemokines in disease. R.G. Landes Company: Austin, 1996;103-16.
80. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995;270:27348-57.
81. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Strieter RM. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994;179:1409-15.
82. Hosaka S, Akahoshi T, Wada C, Kondo H. Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994;97:451-7.
83. Rampart M, Herman AG, Grillet B, Opdenakker G, Van Damme J. Development and application of a radioimmunoassay for interleukin-8: Detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab Invest 1992;66:512-8.
84. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Walz A, Strieter RM. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994;94:1012-8.
85. Koch AE, Kunkel SL, Shah MR, Hosaka S, Halloran MM, Haines GK, Burdick MD, Pope RM, Strieter RM. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995;155:3660-6.
86. Hogan M, Sherry B, Ritchlin C, Fabre M, Winchester R, Cerami A, Bucala R. Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. Cytokine 1994;6: 61-9.
87. Castor CW, Andrews PC, Swartz RD, Ellis SC, Hossler PA, Clark MR, Matteson EL, Sachter EF. The origin, variety, distribution and biological fate of connective tissue activating peptide III isoforms: characteristics in patients with rheumatoid, renal, and arterial disease. Arthritis Rheum 1993;36:1142-53.
88. Isik FF, Rand RP, Gruss JS, Benjamin D, Alpers CE. Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 1996;61:71-6.
89. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997;186:131-7.
90. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Strieter RM. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
91. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
92. Nicosia RF, Bonanno E, Smith M. Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 1993;154:654-61.
93. Gamble JR, Matthias LJ, Meyer G, Kaur P, Russ G, Faull R, Berndt MC, Vadas MA. Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 1993;121:931-43.
94. Maeda S, Sawai T, Uzuki M, Takahashi Y, Omoto H, Seki M, Sakurai M. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:970-5.
95. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
96. Hembry RM, Bagga MR, Reynolds JJ, Hamblen DL. Immunolocalisation studies on six matrix metalloproteinases and their inhibitors. TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 1995;54:25-32.
97. Szekanecz Z, Haines GK, Koch AE. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol 1997;50:314-9.
98. Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 1996;55:230-6.
99. Ronday HK, Smits HH, Van Muijen GN, Pruszczynski MS, Dolhain RJ, Van Langelaan EJ, Breedveld FC, Verheijen JH. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35:416-23.
100. Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 1995;7:229-34.
101. Saiki I, Murata J, Makabe T, Nishi N, Tokura S, Azuma I. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). Jpn J Cancer Res 1990;81:668-75.
102. Nicosia RF, Bonanno E. Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am J Pathol 1991;138:829-33.
103. Albelda SM. Differential expression of integrin cell-substratum adhesion receptors on endothelium. EXS 1991;59:188-92.
104. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990;4:2868-80.
105. Szekanecz Z, Szegedi G. Cell adhesion receptors: structure, function and clinical aspects. Orv Hetil 1992;133:135-42.
106. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994;8:929-38.
107. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
108. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol 1995;5:69-74.
109. Bauer J, Margolis M, Schreiner C, Edgell CJ, Azizkhan J, Lazarowski E, Juliano RL. In vitro model of angiogenesis using a human endothelium-derived permanent ceil line: contributions of induced gene expression. G-proteins, and integrins. J Cell Physiol 1992;153: 437-49.
110. El Gabalawy H, Wilkins J. Beta 1 (CD29) integrin expression in rheumatoid synovial membranes: an immunohistologic study of distribution patterns. J Rheumatol 1993;20:231-7.
111. Johnson B, Haines GK, Harlow LA, Koch AE. Adhesion molecule expression in human synovial tissues. Arthritis Rheum 1993;36:137-46.
112. Nguyen M, Strubel NA, Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 1993;365:267-9.
113. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-4.
114. Maier JA, Delia D, Thorpe PE, Gasparini G. In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antiody TEC-11. Anticancer Drugs 1997;8:238-44.
115. Kumar P, Wang JM, Bernabeu C. CD 105 and angiogenesis [editorial]. J Pathol 1996;178:363-6.
116. Wilkinson LS, Edwards JCW, Poston RN, Haskard DO. Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest 1993;68:82-8.
117. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ-W, Koch AE. Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin Immunol Immunopathol 1995;76:180-6.
118. Camussi G, Montrucchio G, Lupia E, De Martino A, Perona L, Arese M, Vercellone A, Toniolo A, Bussolino F. Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism. J Immunol 1995;154:6492-501.
119. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 1995;22:1651-4.
120. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1993;20:714-7.
121. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. TNFα, a potent inhibitor of cell growth in vitro is angiogenic in vivo. Proc Natl Acad Sci USA 1987;84:5277-81.
122. van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
123. Sugiyama E, Kuroda A, Taki H, Ikemoto M, Hori T, Yamashita N, Maruyama M, Kobayashi M. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995;22:2020-6.
124. Koch AE, Fong TW, Volpert OV, Halloran MM, Bouck NP. Interleukin-4 is an inhibitor of angiogenesis. Arthritis Rheum 1996;39:S304.
125. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995;87:581-6.
126. Angiolillo A, Sgadari C, Tosato G. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 1996;795:158-67.
127. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Clin Exp Rheumatol 1996;14:155-62.
128. Tanabe BK, Abe LM, Kimura LH, Reinker KA, Yamaga KM. Cytokine mRNA repertoire of articular chondrocytes from arthritic patients, infants, and neonatal mice. Rheumatol Int 1996;16:67-76.
129. Pepper MS, Ferrara N, Orci L, Montesano, R. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 1995;108:73-83.
130. Waring PM, Carroll GJ, Kandiah DA, Buirski G, Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthtitis Rheum 1993;36:911-5.
131. Hamilton JA, Waring PM, Filonzi EL. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α. J Immunol 1993;150:1496-502.
132. Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 1993;91:1575-81.
133. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
134. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995;210:51-7.
135. Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, Itoh Y, Okanoue T. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997;158:5536-44.
136. Wooley PH, Schaefer C, Whalen JD, Dutcher JA, Counts DF. A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol 1997;24:890-8.
137. Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP. Immunolocalization of the angiogenesis inhibitor thrombospondin in human arthritic synovial tissues. Pathobiology 1993;161:1-6.
138. Taraboletti G, Belotti D, Giavazzi R. Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. EXS 1991;59:210-3.
139. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regualtion of thrombospondin-1. Science 1994;265:1582-4.
140. DiPietro LA, Nebgen DR, Polverini PJ. Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis. J Vasc Res 1994;31:178-85.
141. Koch AE, Szekanecz Z, Friedman J, Haines GK, Langman CB, Bouck NP. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol, in press.
142. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989;32:1065-73.
143. Firestein GS, Paine MM, Boyle DL. Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression. Arthritis Rheum 1994;37:193-200.
144. Koch AE, Burrows J, Cho M, Polverini PJ, Leibovich, SJ. Thiol containing compounds inhibit the production of macrophage-derived angiogenic activity. Agents Actions 1991;34:350-7.
145. Koch AE, Cho M, Burrows J, Leibovich SJ, Polverini PJ. Inhibition of production of macrophage-derived angiogenic activity by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem Biophys Res Commun 1988;154:205-12.
146. Saura R, Matsubara T, Mizuno K. Inhibition of neovascularization in vivo by gold compounds. Rheumatol Int 1994;14:1-7.
147. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor. AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1995;166:196-206.
148. Josefsson E, Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum 1997;40:154-63.
149. Colville-Nash PR, El-Ghazaly M, Willoughby DA. The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation. Agents Actions 1993;38:126-34.
150. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
151. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;175:1135-8.
152. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291-9.
153. Peacock DJ, Banquerigo ML, Brahn E. A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol 1995;160:178-84.
154. Sewell KL, Breedveld F, Furrie E, O'Brien J, Brinckerhoff C, Dynesius-Trentham R, Nosaka Y, Trentham DE. The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol 1996;167:195-204.
155. Trentham DE, Dynesius-Trentham RA. Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Rheum Dis Clin North Am 1995;21:817-34.
156. Kloppenburg M, Breedveld FC, Terwiel JP, Mallee C, Dijkmans BA. Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 1994;37:629-36.
157. Carlson RP, Hartman DA, Tomchek LA, Walter TL, Lugay JR, Calhoun W, Sehgal SN, Chang JY. Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993;266:1125-38.
158. Carlson RP, Baeder WL, Caccese RG, Warner LM, Sehgal SN. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases. Ann N Y Acad Sci 1993;685P:86-113.
159. Nemoto K, Mae T, Abe F, Takeuchi T. Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice. Ann N Y Acad Sci 1993;685P:148-54.
160. Moses MA. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 1993;8(11 Suppl):67S-69S.
161. Nakamura S, Kamihagi K, Satakeda H, Katayama M. Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage: increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum 1996;39:539.
162. Cotran RS. Endothelial cells. In: Kelley WN, Harris ED, Ruddy S, Sledge C, eds. Textbook of Rheumatology, 3rd edition. Philadelphia: W.B. Saunders Co., 1989;389-411.
163. van Dinther-Janssen ACHM, Horst E, Koopman G, Newmann W, Scheper RJ, Meijer CJ, Pals ST. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 1991;147:4207-10.
164. Mican JM, Metcalfe DD. Arthritis and mast cell activation. J Allergy Clin Immunol 1990;86:677-83.
165. Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J Investig Med 1995;43:28-38.
166. Elices MJ, Tsai V, Strahl D, Goel AS, Tollefson V, Arrhenius T, Wayner EA, Gaeta FC, Fikes JD, Firestein GS. Expression and functional significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature. J Clin Invest 1994;93:405-16.
167. Koch AE, Turkiewicz W, Harlow LA, Pope RM. Soluble E-selectin in arthritis. Clin Immunol Immunopathol 1993;69:29-35.
168. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO. Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993;92:412-8.
169. Rathanaswami P, Hachicha M, Wong WL, Schall TJ, McColl SR. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on interleukin-8 gene expression in synovial fibroblasts. Evidence that interleukin-8 is the major neutrophil-activating chemokine released in response to monokine activation. Arthritis Rheum 1993;36:1295-304.
170. Presta M, Rusnati M, Urbinati C, Tanghetti E, Statute M, Pozzi A, Gualandris A, Ragnotti G. Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. EXS 1991;59:205-9.
171. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
172. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M. Monoclonal anti-TNF-a antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995;144:195-221.
173. Kingsley G, Panayi G, Lanchbury J. Immunotherapy of rheumatic diseases - practice and prospects. Immunol Today 1991;12:177-9.
174. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) Fc fusion protein. N Engl J Med 1997;337:141-147.
175. Arend WP. Cytokine inhibitors and receptor antagonists. In: Rich RR, Fleisher TA, Schwartz BD, Shearer WT, Strober W, eds. Clinical immunology. Principles and practice. St. Louis: Mosby, 1996; 2046-55.
176. Drevlow BE, Lovis R, Hang R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RM. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996;39:257-65.
177. Evans CH, Robbins PD. Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 1996;8:230-24.
178. Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, McCarthy JB. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994;94:655-62.
179. Corkill MM, Kirkham BW, Haskard DO, Barbatis C, Gibson T, Panayi GS. Gold treatment of rheumatoid arthritis decreases synovial expression of the endothelial leukocyte adhesion receptor ELAM-1. J Rheumatol 1991;18:1453-60.
180. Bennett CF, Condon TP, Grimm S, Chan H, Chiang M-Y. Inhibition of endothelial cell adhesion molecule expression with anti-sense oligonucleotides. J Immunol 1994;152:3530-40.